Program
GXV-813
In Novartis's pipeline, M4 agonist
. Its studies are mostly in Schizophrenia, led by Novartis.
Furthest: phase 2, since Mar 9, 20261 company-led study, 1 open or runningNext primary completion: Jul 29, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 11 open or running | phase 2since Mar 9, 2026 | Mar 9, 2026 | Jul 29, 2027phase 2 · NCT07467993 |
- Named in Novartis’s own pipeline as
GXV813
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 9, 2026First study: phase 2 study in SchizophreniaFirst studyNCT07467993 · 142 planned · United States, Bulgaria
Ahead
- Jul 29, 2027Primary completion: phase 2 study in SchizophreniaNCT07467993
TargetBeta
“M4 agonist”the company's pipeline, read by Claude · source
Other programs on CHRM4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Glycopyrrolaterule | Novartis | phase 4 | 87 |
| xanomelinerule | Bristol-Myers Squibb | phase 4 | 38 |
| emraclidine | AbbVie | phase 2 | 18 |
| ABBV-1042 | AbbVie | phase 1 | 1 |
| BMS-986521 | Bristol-Myers Squibb | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07467993Schizophrenia · United States, Bulgaria | 2 | Recruiting | Jul 29, 2027 | 142 |
How it is read
Names in the registry
- “GXV813”, 1 entry
Conditions, from the studies’ own filings
- Schizophrenia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.